| Schedule of Breakdown of Stock-Based Compensation by Categories |
The breakdown of stock-based compensation by categories for the six months ended December 31, 2024 and 2023 are summarized below:
|
|
|
For the
Six months
ended
December 31,
2024
|
|
For the
Six months
ended
December 31,
2023
|
|
Research and development
|
|
$
|
7,131 |
|
$
|
453,968 |
|
General and administrative
|
|
|
425,125 |
|
|
740,685 |
|
Total stock-based compensation
|
|
$
|
432,256 |
|
$
|
1,194,653 |
|
The breakdown of stock-based compensation by categories for the three and nine months ended September 30, 2025 and 2024 are summarized below:
|
|
|
For the
Three months
ended
September 30,
2025
|
|
For the
Three months
ended
September 30,
2024
|
| |
|
(Unaudited)
|
|
(Unaudited)
|
|
Research and development
|
|
$
|
10,414 |
|
$
|
—
|
|
General and administrative
|
|
|
142,007 |
|
|
—
|
|
Total stock-based compensation
|
|
$
|
152,421 |
|
$
|
—
|
|
|
|
For the
Nine months
ended
September 30,
2025
|
|
For the
Nine months
ended
September 30,
2024
|
| |
|
(Unaudited)
|
|
(Unaudited)
|
|
Research and development
|
|
$
|
30,903 |
|
$
|
—
|
|
General and administrative
|
|
|
439,711 |
|
|
—
|
|
Total stock-based compensation
|
|
$
|
470,614 |
|
$
|
—
|
|
| Schedule of Stock Option Activities |
A summary of information related to stock option activities during the year ended June 30, 2024 and for the six-month transition period ended December 31, 2024 is as follows:
|
|
|
Number of
Shares
|
|
Weighted-
Average
Grant Date
Fair Value
per share
|
|
Balance of unvested early-exercised stock option at June 30, 2023*
|
|
2,633,082 |
|
|
$
|
0.46 |
|
Vested early-exercised stock option*
|
|
(2,633,082 |
)
|
|
$
|
0.46 |
|
Balance of unvested early-exercised stock option at June 30, 2024
|
|
—
|
|
|
$
|
—
|
|
Granted-2023 Plan stock option
|
|
3,600,000 |
|
|
$
|
0.65 |
|
Vested 2023 Plan stock option
|
|
(583,332 |
)
|
|
$
|
0.65 |
|
Balance of unvested early-exercised stock option at December 31, 2024
|
|
3,016,668 |
|
|
$
|
0.65 |
|
A summary of information related to stock option activities during the six-month transition period ended December 31, 2024 and for the nine months ended September 30, 2025 is as follows:
|
|
|
Number of
Shares
|
|
Weighted-
Average
Grant Date
Fair Value
per share
|
|
Balance of unvested early-exercised stock options at June 30, 2024
|
|
—
|
|
|
$
|
—
|
|
Granted – 2023 Plan stock option
|
|
3,600,000 |
|
|
$
|
0.65 |
|
Vested 2023 Plan stock option
|
|
(583,332 |
)
|
|
$
|
0.65 |
|
Balance of unvested stock options at December 31, 2024
|
|
3,016,668 |
|
|
$
|
—
|
|
Vested 2023 Plan stock option
|
|
(666,634 |
)
|
|
$
|
0.65 |
|
Balance of unvested stock options at September 30, 2025 (Unaudited)
|
|
2,350,034 |
|
|
$
|
0.65 |
|
| Schedule of Estimated the Fair Value of the Stock Options |
The Company estimated the fair value of the stock options using the Black-Scholes option pricing model. The fair value of stock options issued was estimated using the following assumptions:
| Grant date | | May 27,
2022 | | Exercise price | | $ | 0.001 | | | Estimated stock price | | $ | 0.11 | | | Expected volatility | | | 120.0 | % | | Expected term (in years) | | | 4.00 | | | Risk-free interest rate | | | 3.00 | % | The Company estimated the fair value of the stock options using the Black-Scholes option pricing model. The fair value of stock options issued was estimated using the following assumptions:
|
Grant date
|
|
October 30,
2024
|
|
Exercise price
|
|
$
|
0.815 |
|
|
Stock price
|
|
$
|
0.815 |
|
|
Expected volatility
|
|
|
101.5 – 101.6 |
% |
|
Expected term (in years)
|
|
|
5.5 – 6.0 |
|
|
Risk-free interest rate
|
|
|
4.16 – 4.17 |
% |
|
|